Achieve Life Sciences, Inc. (NASDAQ: ACHV)

Achieve Life Sciences, Inc. is a late stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline for the treatment of nicotine dependence. The company aims to address both traditional cigarette smoking and electronic cigarette use through a novel therapeutic that mimics nicotine activity while reducing cravings and reward. Its lead product candidate is currently under review by the U. S. Food and Drug Administration for smoking cessation indication with a target action date of June 20 2026.

As a pre revenue company Achieve Life Sciences does not generate sales from approved products. Its current funding comes from government research grants such as the National Institute on Drug Abuse award for electronic cigarette cessation studies and from potential milestone payments under its license agreements with partners. The company anticipates future revenue from product sales royalties and milestone receipts once cytisinicline receives regulatory approval and is launched commercially.

• no_segments_reported.

Within the smoking cessation therapeutics market Achieve Life Sciences positions itself as a potential first new prescription medicine in over two decades that targets nicotine dependence for both smoking and electronic cigarette cessation. Its main competitors include the existing prescription therapies varenicline and bupropion as well as widely used nicotine replacement therapies such as patches gum and lozenges. The company differentiates cytisinicline through demonstrated efficacy a favorable safety profile and flexible dosing regimens of six or twelve weeks which may improve adherence compared with current options.

The company intends to serve patients who seek to quit smoking or electronic cigarette use as well as healthcare providers who prescribe cessation therapies and pharmacies that dispense the medication. Payors such as insurance companies and government health programs are also expected to be part of the distribution chain once the product is approved. No specific customer names are disclosed in the filing.